Background: Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic review (2019–2025) synthesizes research results regarding the efficacy and safety of dienogest (DNG...
Zuzanna Betiuk, Martyna Błażyca, Martyna Bartoszczyk et al.· Journal of Clinical Medicine· 0 citations
The classification of endometrial cancer based on histological examination often fails to accurately predict treatment outcomes for patients. The Cancer Genome Atlas (TCGA) has proposed a new molecular model that more accurately identifies the tumour subtype, enabling more precise treatment. However, its implementation...
Natalia Gierulska, Julia Orzelska, Katarzyna Lachowska et al.· International Journal of Mol...· 0 citations
BRCA1/2 mutation status is a key biomarker in the management of ovarian cancer, supporting personalized treatment strategies and improving patient outcomes, and emerging mechanisms of resistance to PARP inhibitors remain a significant therapeutic challenge.
Weronika Pawul, Paulina Opoka, Agata Dusza et al.· Frontiers in Oncology· 0 citations
Dato-DXd demonstrates robust clinical activity in patients with BC, providing superior disease control with a favorable safety profile compared to conventional chemotherapy, and preclinical data suggest that the induction of ICD may contribute to reshaping a heterogeneous TME.
Julia Piekarz, Natalia Picheta, Jakub Pobideł et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
